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Summary
Background Introduced in the mid-1990s, minimally
invasive pancreatic surgery (MIPS) developed slowly
over the next two decades, and its real-life benefits
remained unclear.
Methods In this review, the current status and evi-
dence on the most common types of MIPS, such as
minimally invasive pancreatoduodenectomy (MIPD),
distal pancreatectomy, enucleation, and central pan-
createctomy are presented.
Results Minimally invasive distal pancreatectomy
(MIDP) is the most frequently used procedure among
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these, and its indications are nowadays expanding.
MIDP for benign and low-grade malignant tumors is
advantageous compared to the open approach, sug-
gesting less intraoperative blood loss, shorter hospital
stay, faster functional recovery, and better quality of
life. The oncological adequacy of MIDP in pancreatic
cancer is unclear, as no randomized trials have been
published. In contrast, MIPD is a technically chal-
lenging procedure performed in a small number of
centers and in a selected group of patients. Its use
remains controversial, as conflicting data have been
reported in the literature. Annual volume and learn-
ing curve seem to be the key determinants of safety in
MIPD. Minimally invasive pancreatic enucleation and
central pancreatectomy are less common. Although
one randomized trial was published on minimally
invasive vs. open central pancreatectomy, current
evidence on these procedures is mostly based on ret-
rospective, single-institution series clearly affected by
selection bias and small sample size.
Conclusion Well-designed prospective studies based
on national registries are needed to expand knowledge
on MIPS and determine its role in pancreatic surgery.
To facilitate further development of MIPS, it has to in-
tegrate effectively with the outcome-improving effect
of a dedicated pancreatic team.
Keywords Laparoscopic surgery · Pancreatoduo-
denectomy · Distal pancreatectomy · Enucleation ·
Central pancreatectomy
Main novel aspects
This manuscript summarizes current data and evidence
level on minimally invasive pancreatic surgery. Its main
types such as pancreatoduodenectomy, distal pancre-
atectomy, enucleation, and central pancreatectomy are
included.
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Introduction
Minimally invasive pancreatic surgery (MIPS) was in-
troduced in the mid-1990s by Gagner and co-workers,
who reported laparoscopic pancreatoduodenectomy,
enucleation, and distal pancreatectomy [1, 2]. De-
spite these early reports, further implementation of
MIPS into clinical practice has been rather slow. Pos-
sible reasons for this are the anatomic complexity of
the region, limitations of laparoscopic equipment rel-
ative to pancreatic surgery, the technically demanding
nature of MIPS, and a high risk of postoperative com-
plications.
In the early period of MIPS, minimally invasive
distal pancreatectomy (MIDP) and enucleation were
mostly considered in selected patients as there was
no need for pancreatic anastomoses [3, 4]. The se-
lection criteria for these procedures included tumor
type, tumor size, location, involvement of adjacent
tissues, and patient characteristics. In contrast, min-
imally invasive pancreatoduodenectomy (MIPD) was
deemed technically challenging and associated with
high perioperative risks [5]. Furthermore, its real-life
benefits were largely unclear to surgeons. According
to the US National Cancer Database (NCDB) review
for 2010–2011, patients with lesions in the pancreatic
tail were three times more likely to be operated on by
MIPS than those with lesions in the pancreatic head
[6]. The same study demonstrated that only 13.5% of
all patients were subjected to MIPS, while 86.5% were
operated on by the open approach.
The first review articles comparing MIPS and its
open counterpart found comparable morbidity and
mortality, although longer operative time, less blood
loss, and shorter hospital stay were typical for the for-
mer [3, 5, 7, 8]. At the same time, these studies un-
derscored the low evidence level and selection bias in
the minimally invasive arm. Over the past few years,
the evidence level on MIPS has somewhat increased
as prospective studies, randomized controlled trials
(RCTs), and consensus articles have emerged in the
literature. In this study, the current evidence on MIPS
and its future perspectives are reviewed.
Minimally invasive distal pancreatectomy
The first MIDP reported by Cuschieri was performed
for chronic pancreatitis in 1994 [9]. The proportion of
MIDP grew exponentially over the next two decades.
In the American population-based study, Tran Cao
et al. found that the rate of MIDP has tripled from
2.4% of all distal pancreatectomies in 1998 to 7.3%
in 2009 [10]. Data from the nationwide study in the
Netherlands demonstrate a significant increase in the
proportion of MIDP—from 9 to 47% [11]. In Norway,
MIDP currently accounts for 59% of all distal pancre-
atectomies nationwide [12].
Multiple case–control studies examining outcomes
of minimally invasive and open distal pancreatec-
tomy (ODP) have been published to date. Systematic
reviews of these studies report reduced intraoperative
blood loss, less red blood cell transfusion, and shorter
hospital stay for MIDP, but comparable incidence of
postoperative pancreatic fistula (POPF), morbidity,
and mortality [13, 14]. MIDP was also reported to
be associated with relatively high spleen preservation
rates compared to its open counterpart, which was
explained by the magnified and enhanced visualiza-
tion facilitating dissection along the splenic vessels
and clear identification of small arteries and veins
[15, 16]. However, this evidence is based predom-
inantly on retrospective series affected by selection
bias. Some studies even observed less postoperative
complications following MIDP [7, 17]. At the same
time, management of the pancreatic stump during
MIDP as one of the most crucial steps of this proce-
dure is as problematic as in open surgery, resulting in
similar rates of POPF (19.1 vs. 19.9%, p= 0.73, respec-
tively) [7]. The only RCT published to date suggests
less blood loss, longer operative time, lower clinically
relevant (grade B/C) delayed gastric emptying rates,
shorter time to functional recovery, and better quality
of life for MIDP compared with ODP [18]. Interest-
ingly, several prospective studies focusing on costs
found MIDP to be as cost effective as ODP [19–21].
The indications for MIDP have changed signifi-
cantly over time. Although initially applied mostly
for benign and low-grade malignant tumors, MIDP
is becoming increasingly used for ductal adenocar-
cinoma. In France, its proportion in patients with
cancer has doubled from 7.3% in 2007 to 14.8% in
2012 [22]. In the Netherlands, the proportion of
MIDP for ductal adenocarcinoma has increased from
5 to 51% [11]. Several systematic reviews published
on this topic have agreed that typical advantages of
the minimally invasive technique also translate into
surgery for pancreatic cancer [23, 24], but, most im-
portantly, the long-term oncologic outcomes were
comparable between MIDP and ODP [25, 26]. At the
same time, MIDP was associated with less lymph
node yield, smaller tumor size, and less perineural
invasion, which was a result of early stage cancer and
a selection bias in the minimally invasive arm.
The recent worldwide survey among pancreatic
surgeons performing MIDP demonstrated that only
12% of surgeons found no contraindications for MIDP
[27]. In a similar pan-European survey, 45% of sur-
geons claimed that they had insufficient training in
MIDP for all indications [28]. The recent American
nationwide study evaluating patient selection fac-
tors concluded that MIDP was more often applied
in patients with benign lesions and in case of body
mass index (BMI) 30–40kg/m2, whereas ODP was
a preferable option for tumors >5cm and if multivis-
ceral resection was needed [29]. These findings were
further confirmed by the data from the NCDB, which
found that pancreatic ductal adenocarcinoma was
independently associated with opting for the open
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approach [6]. Thus, questions about the oncologic
adequacy and possible limits of MIDP in the setting
of cancer remain unanswered. A pan-European RCT
(DIPLOMA) on minimally invasive vs. open distal
pancreatectomy for cancer is currently running and
its results are much anticipated [30].
Laparoscopic versus robotic distal pancreatectomy
Several systematic reviews and meta-analysis have
been published on laparoscopic vs. robotic distal pan-
createctomy [31–33]. These suggest that the robotic
approach is associated with longer operative time,
shorter hospital stay, and higher spleen preservation
rates compared with laparoscopy. However, evidence
comes mostly from retrospective series. In a prospec-
tive study, Butturini et al. observed longer operative
time and doubled costs for the robotic approach, but
similar postoperative and oncologic outcomes [34].
Another prospective study compared robotic with
laparoscopic single-site distal pancreatectomy and
found longer operative time for the robotic approach,
while postoperative and oncologic outcomes were
similar [35]. In contrast, analysis of the US NCDB
demonstrated comparable oncologic outcomes, but
a higher conversion rate for laparoscopic distal pan-
createctomy [36].
To date, no clear evidence-based recommendations
regarding MIDP can be set, although clinical prospec-
tive series also from national quality-controlled reg-
istries are increasingly published. Clear algorithms
for local development of an MIDP service should be
based on a structured training program. A recent
consensus study from the European association for
endoscopic surgery reported a significant reduction
in operative time as a learning curve parameter after
10–17 laparoscopic distal pancreatectomies [37]. Con-
version rate and intraoperative blood loss were con-
sidered as possible indicators of the learning curve in
MIDP.
Minimally invasive pancreatoduodenectomy
Since the introduction of MIPD more than 20 years
ago, the attitude of surgeons towards this proce-
dure has been controversial. First and foremost,
MIPD is a highly complex procedure with a steep
learning curve. Data from a high-volume center
suggest decreased blood loss and conversion rate af-
ter 20 MIPDs, a decrease in pancreatic fistula after
40 procedures, and a decrease in operative time af-
ter 80 procedures [38]. At the same time, given the
relatively small number of centers performing MIPD
and strict patient selection criteria, its advantages
over open pancreatoduodenectomy (OPD), as well
as its oncologic adequacy, were unclear. According
to a recent pan-European survey, only 21% of pan-
creatic surgeons have experience with MIPD [28].
Interestingly, 65% of responders view laparoscopy in
pancreatoduodenectomy as a technical problem. The
most frequently mentioned technical concern during
MIPD is construction of pancreatic anastomosis [27].
During the first decade of laparoscopic pancreato-
duodenectomy in the US, the latter was performed in
only 4.4% of patients referred to pancreatoduodenec-
tomy [39]. The analysis of the NCDB from Sharpe and
co-workers demonstrated that low-volume centers
performing <10 laparoscopic pancreatoduodenec-
tomies annually had a twofold increase in 30-day
mortality compared to OPD [40]. Another study fo-
cused on NCDB reported decreased 90-day mortality
in centers performing >6 MIPD annually [41]. Thus,
outcomes of MIPD seem to depend highly on the
annual volume of the center.
Systematic reviews and meta-analyses comparing
MIPD and OPD report less intraoperative blood loss,
a lower transfusion rate, longer operative time, and
shorter hospital stay for the former [42–45]. The onco-
logic outcomes were equivalent to those in OPD [41,
45]. However, these reports are largely based on ret-
rospective studies affected by selection bias, and thus
should be interpreted with caution. Three RCTs on
MIPD vs. OPD have been published over the past few
years. The first study conducted in a single institu-
tion in India demonstrated longer operative time, less
blood loss, and shorter hospital stay (7 vs. 13 days,
p= 0.001) for laparoscopic pancreatoduodenectomy
compared with OPD for periampullary tumors [46].
Postoperative outcomes were comparable. This study
was performed in a private hospital with a specific
focus on laparoscopic surgery, with few surgeons
involved and who had passed the training curve
by several hundreds of laparoscopic pancreatoduo-
denectomies. This trial is therefore to be considered
an expert trial. Due to an imbalance in benign to ma-
lignant cases and more pancreatic cancers in the open
group, this trial will not be able to present any useful
information on long-term oncological outcomes.
Another single-center RCT (PADULAP) reported
less grade≥3 postoperative complications, a lower
comprehensive complication index, and shorter hos-
pital stay for the laparoscopic approach [47]. In
contrast, the Dutch multicenter randomized LEOP-
ARD-2 trial was prematurely terminated by the safety
monitoring board due to more complication-related
mortality in the laparoscopic arm (10 vs. 2%) [48].
Surgeon experience, learning curve, and annual vol-
ume are thought to affect this outcome. Of note,
among the patients included, there were no benefits
in short-term outcomes or functional recovery in the
laparoscopy group (which was the primary aim of the
study).
MIPD and vascular resection
Evidence remains scarce regarding the role of MIPD
in the setting of vascular resection for tumor inva-
sion. Only a few case series from expert centers have
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been published on MIPD with vascular resection and
reconstruction [49–52]. These mostly include ve-
nous resections and report acceptable perioperative
outcomes. The only comparative study published by
Croome et al. suggests comparable surgical and onco-
logic outcomes betweenMIPD with vascular resection
and its open counterpart [49]. In the LEOPARD-2 trial,
intraoperative vascular complications were the main
cause for conversions and intraoperative complica-
tions leading to a few of the deaths that lead the trial
to be stopped prematurely for safety reasons.
Laparoscopic versus robotic
pancreatoduodenectomy
The review of the American College of Surgeons
National Surgical Quality Improvement Program
database found that the type of MIPD (laparoscopic
or robotic) was not associated with postoperative
complications [53]. Another similar study from Zim-
merman et al. found that robotic surgery was less
frequently performed for malignancies and was asso-
ciated with more surgical site infections, but a lower
conversion rate compared with laparoscopy [54]. In
contrast, the recent systematic review from Ricci et al.
suggests that the robotic system provided the best
outcomes among minimally invasive techniques ap-
plied for pancreatoduodenectomy, while laparoscopy
was associated with a high risk of postoperative com-
plications, bleeding, and biliary leakage [55].
A recommendation for MIPD based on current evi-
dence cannot be made due to low data quality. In view
of complex reconstruction during pancreatic head re-
section, the robotic approach might have a greater
potential.
Other minimally invasive procedures
Less frequently utilizedminimally invasive procedures
on the pancreas are enucleation and central pancrea-
tectomy. Compared with pancreatoduodenectomy or
distal pancreatectomy, these are parenchyma-spar-
ing procedures aimed at preventing development
of pancreatic exocrine and endocrine insufficiency.
Minimally invasive pancreatic enucleation (MIPE)
has clear indications applicable also in open surgery:
benign and low-grade malignant tumors with a small
size ≤4cm, and a clear distance from the main pan-
creatic duct.
A small number of case–control studies have been
published on minimally invasive vs. open pancre-
atic enucleation. These report shorter operative time,
less blood loss, and reduced hospital stay for the for-
mer [56–59]. A systematic review from Guerra et al.
confirmed these findings, while the rates of clinically
relevant POPF and major complications were similar
[60]. Although initially considered for left-sided pan-
creatic lesions only, MIPE has also been successfully
applied for tumors in the pancreatic head [59, 61].
Interestingly, both the laparoscopic and the robotic
approach have been equally successful in pancreatic
enucleation, as reported in the aforementioned stud-
ies. At the same time, strict patient selection criteria
and a lack of randomized trials on this topic limit cur-
rent knowledge on the role of MIPE.
Minimally invasive central pancreatectomy (MICP)
is normally applied for benign or low-grade malig-
nant lesions like small neuroendocrine neoplasms lo-
cated in the pancreatic body and neck, which cannot
be removed by MIPE due to tumor proximity to the
main pancreatic duct. At the same time, this proce-
dure bears risks and challenges, such as technically
demanding pancreatic anastomosis and two poten-
tial sources of POPF. Only small case series had been
published on MICP until recently [62, 63]. One of
the first comparative studies between minimally in-
vasive and open central pancreatectomy conducted
by Song et al. demonstrated longer operative time
but shorter hospital stay for MICP [64]. Another sim-
ilar report from Asia suggests less blood loss as well
as shorter first flatus and diet start times following la-
paroscopic central pancreatectomy [65]. Quality of life
parameters were higher for laparoscopy compared to
the open approach yet without statistical significance.
A systematic review and meta-analysis by Xiao and
co-workers demonstrated similar POPF rates, morbid-
ity, and incidence of postoperative exocrine and en-
docrine insufficiency between minimally invasive and
open central pancreatectomy [66]. However, the re-
operation rate was higher for MICP. Interestingly, the
use of pancreaticojejunostomy and pancreaticogas-
trostomy was almost equal during MICP, while POPF
rates between them were similar. Finally, an RCT on
robot-assisted laparoscopic vs. open central pancre-
atectomy published by Chen et al. suggests shorter
operative time, less blood loss, lower incidence of clin-
ically relevant POPF, and faster postoperative recovery
after laparoscopy [67]. The long-term data on MICP
from this trial are awaited.
Future perspectives
More than two decades have passed since the intro-
duction of MIPS and five RCTs have been published
to date (Table 1). Yet implementation of MIPS has
advanced differently for pancreatoduodenectomy and
distal pancreatectomy. If the progress of MIDP over
the past two decades and its perspectives are obvi-
ous, the future of MIPD is unclear. MIDP is cur-
rently gaining widespread acceptance among pancre-
atic surgeons worldwide and will likely soon replace
its open counterpart. The main question yet to be
answered regarding MIDP is whether it is as oncolog-
ically effective and safe as the open approach. Hope-
fully, the ongoing DIPLOMA trial on minimally inva-
sive vs. open distal pancreatectomy for ductal ade-
nocarcinoma will give all answers and allow for the
extension of boundaries for MIDP and its full recogni-
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Table 1 Summary of randomized controlled trials on minimally invasive pancreatic surgery
Author/year Number of patients Type of procedure Tumor type Main outcome
De Rooij/2018 [18] 108 ODP vs. MIDP All types MIDP is associated with reduced time to functional recovery
(p< 0.001)
Palanivelu/2017 [46] 64 OPD vs. MIPD Periampullary cancer MIPD offered shorter hospital stay (P= 0.001)
Van Hilst/2019 [48] 105 OPD vs. MIPD All types MIPD is associated with more complication-related deaths
(p= 0.2). No difference between groups in time to functional
recovery
Poves/2018 [47] 66 OPD vs. MIPD – MIPD resulted in a shorter hospital stay (p= 0.024) and
a more favorable postoperative course (p= 0.04)
Chen/2017 [67] 100 OCP vs. MICP Benign or borderline MICP is associated with significantly shorter hospital stay
(p= 0.002), reduced operative time (p= 0.002), blood
loss (p< 0.001), clinically relevant pancreatic fistula
rate (p= 0.043), and expedited postoperative recovery
(p< 0.001)
ODP open distal pancreatectomy, MIDP minimally invasive distal pancreatectomy, OPD open pancreatoduodenectomy, MIPD minimally invasive pancreatoduo-
denectomy, OCP open central pancreatectomy, MICP minimally invasive central pancreatectomy
tion. Furthermore, the learning curve and implemen-
tation of MIDP into clinical practice is rather straight-
forward and technically feasible. Thus, it has a good
chance of becoming the “gold standard” in the near
future.
The situation is rather different with MIPD. The ra-
tionale for its use remains controversial. Although
some studies report typical advantages of the mini-
mally invasive approach also for MIPD, high mortal-
ity observed in a number of population-based studies
and in the recent Dutch RCT warrants further inves-
tigation. This problem was shown to be associated
with low-volume centers performing MIPD. Hence,
one possible solution could be centralizing the health
care system and concentrating MIPD in high-volume
centers with a sufficient level of expertise, where the
benefits of MIPD can be perceived. All in all, more
evidence is needed to clarify the utility of MIPD.
MIPE and MICP are limited to a small number of
selected patients. However, these procedures merit
further scrutiny, as they bear significant advantages
over formal resections in terms of preserving pancre-
atic gland function and improving patients’ quality of
life. Well-designed multicenter RCTs are needed to
proceed with the assessment of MIPE and MICP.
The first consensus expert meeting on MIDP and
MIPD is awaited inMarch 2019, presumably leading to
evidence-based recommendations regarding the rou-
tine implementation of minimally invasive surgery for
pancreatic disease.
In conclusion, although the outcomes both for
minimally invasive and open pancreatic surgery are
dependent on the technical skills of the single sur-
geon, the optimal clinical environment and a dedi-
cated pancreatic team plays a greater role in man-
aging patient selection, safe surgery, and overcoming
postoperative complications [68]. To facilitate further
development of MIPS, it has to integrate effectively
with the outcome-improving effect of a dedicated
pancreatic team.
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